{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:46:19Z","timestamp":1785757579971,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013272","name":"Third Health Funds","doi-asserted-by":"publisher","award":["PS\/688\/PS_P3\/OP4\/ESO4.7\/PS_P3_ESO4.7_A6"],"award-info":[{"award-number":["PS\/688\/PS_P3\/OP4\/ESO4.7\/PS_P3_ESO4.7_A6"]}],"id":[{"id":"10.13039\/100013272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.msard.2026.107063","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:00:59Z","timestamp":1770480059000},"page":"107063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world experience of cladribine treatment in relapsing multiple sclerosis: A Romanian multicenter nationwide study"],"prefix":"10.1016","volume":"108","author":[{"given":"Rodica","family":"Balasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barcutean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1834-582X","authenticated-orcid":false,"given":"Smaranda","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Fulop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Vrinceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Davidescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Dulamea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Simu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Panea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Albu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Filipoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Roman-Filip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Sabau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Adella","family":"Sirbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Lungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalie","family":"Vacaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ignat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107063_bib0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ncl.2023.06.003","article-title":"Leveraging real-world evidence and observational studies in treating multiple sclerosis","volume":"42","author":"Aboseif","year":"2024","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2026.107063_bib0023","article-title":"Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers","volume":"382","author":"Adamec","year":"2023","journal-title":"J Neuroimmunol [Internet]"},{"key":"10.1016\/j.msard.2026.107063_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102945","article-title":"A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis","volume":"52","author":"Bose","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107063_bib0024","article-title":"Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study","volume":"79","author":"Brownlee","year":"2023","journal-title":"Mult Scler Relat Disord [Internet]"},{"issue":"1","key":"10.1016\/j.msard.2026.107063_bib0013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1352458519892555","article-title":"Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment","volume":"26","author":"Cohen","year":"2019","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.msard.2026.107063_bib0008","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107063_bib0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107063_bib0016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107063_bib0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primer"},{"issue":"4","key":"10.1016\/j.msard.2026.107063_bib0045","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study","volume":"3","author":"Freedman","year":"2017","journal-title":"Mult Scler J - Exp Transl Clin"},{"issue":"5","key":"10.1016\/j.msard.2026.107063_bib0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2026.107063_bib0007","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler J"},{"issue":"6","key":"10.1016\/j.msard.2026.107063_bib0009","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"11","key":"10.1016\/j.msard.2026.107063_bib0039","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/1352458516650737","article-title":"Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES","volume":"22","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.msard.2026.107063_bib0026","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107063_bib0031","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200415","article-title":"The Italian Multiple sclerosis register experience with Cladribine","volume":"12","author":"Guerra","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"5","key":"10.1016\/j.msard.2026.107063_bib0040","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2026.107063_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105704","article-title":"Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - results from a German cladribine cohort","volume":"88","author":"Kowarik","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107063_bib0036","first-page":"3","article-title":"Multiple sclerosis: 2023 update","volume":"4","author":"Kuhlmann","year":"2023","journal-title":"Free Neuropathol."},{"key":"10.1016\/j.msard.2026.107063_bib0034","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107063_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123070","article-title":"Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: a real-world, single centre study considering a two-year interval from year-2 dosing","volume":"462","author":"Manni","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107063_bib0012","unstructured":"Mavenclad (cladribin\u0103) \u2013 ANMDMR [Internet]. [cited 2025 July 27]. Available from: https:\/\/www.anm.ro\/mavenclad-cladribina\/."},{"issue":"8","key":"10.1016\/j.msard.2026.107063_bib0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMa"},{"issue":"4","key":"10.1016\/j.msard.2026.107063_bib0020","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","article-title":"Expert-agreed practical recommendations on the use of Cladribine","volume":"11","author":"Meca-Lallana","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2026.107063_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.678817","article-title":"Cladribine treatment for MS preserves the differentiative capacity of subsequently generated monocytes, whereas its administration In Vitro acutely influences monocyte differentiation but not microglial activation","volume":"13","author":"Medeiros-Furquim","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107063_bib0033","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107063_bib0004","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/acn3.51206","article-title":"Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS","volume":"7","author":"Moser","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"15\u201316","key":"10.1016\/j.msard.2026.107063_bib0003","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10354-022-00931-4","article-title":"Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety","volume":"172","author":"Moser","year":"2022","journal-title":"Wien Med Wochenschr 1946"},{"issue":"11","key":"10.1016\/j.msard.2026.107063_bib0044","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/1352458516644676","article-title":"Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO","volume":"22","author":"Naismith","year":"2016","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"issue":"3","key":"10.1016\/j.msard.2026.107063_bib0005","article-title":"Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis","volume":"7","author":"Oh","year":"2021","journal-title":"Mult Scler J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107063_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107063_bib0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/13524585231216004","article-title":"Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: recommendations from a global task force","volume":"30","author":"Parciak","year":"2023","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"3","key":"10.1016\/j.msard.2026.107063_bib0041","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of cladribine effectiveness and safety in Multiple sclerosis: a real-world, multicenter, 2-year follow-up study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2026.107063_bib0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"2","key":"10.1016\/j.msard.2026.107063_bib0037","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.msard.2026.107063_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107063_bib0028","article-title":"Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico","volume":"10","author":"Sauri-Suarez","year":"2024","journal-title":"Mult Scler J - Exp Transl Clin"},{"issue":"6","key":"10.1016\/j.msard.2026.107063_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16250","article-title":"Therapeutic choices and disease activity after 2\u2009years of treatment with cladribine: an Italian multicenter study (CladStop)","volume":"31","author":"Schiavetti","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107063_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935019","article-title":"Expert opinion on the use of cladribine tablets in clinical practice","volume":"13","author":"S\u00f8rensen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107063_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107063_bib0042","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective Treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMa Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107063_bib0017","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107063_bib0032","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis \u2014 Insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107063_bib0019","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clinthera.2018.12.015","article-title":"Benefit-risk assessment of Cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis","volume":"41","author":"Vermersch","year":"2019","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.msard.2026.107063_bib0018","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","article-title":"Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing\u2013remitting multiple sclerosis patients: a monocentric longitudinal observational study","volume":"270","author":"Zanetta","year":"2023","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:04:09Z","timestamp":1785755049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"alternative-id":["S2211034826000994"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107063","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience of cladribine treatment in relapsing multiple sclerosis: A Romanian multicenter nationwide study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107063"}}